MEDP
Medpace Holdings, Inc.
Set alert
- YTD
- +16.09%
- 1 year
- +12.34%
- Open
- 677.85
- Prev close
- 677.56
- Mkt cap
- 18.24B
- Vol
- 219.45K
- Avg vol
- 258.88K
- EPS
- 18.01
- P/E
- 36.20
- Div yield
- 0.00%
More statistics
- Low
- 648.11
- High
- 677.85
- Forward P/E
- 32.84
- Beta
- 1.18
- Short ratio
- 6.09
- Inst. own
- 90.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 8, 2027
- 50-d avg
- 618.33
- 200-d avg
- 529.20
- 1y target
- 651.31
Key statistics
- Market cap
- 18.24B
- Enterprise value
- 18.42B
- Trailing P/E
- 36.20
- Forward P/E
- 32.84
- PEG ratio
- 3.48
- Price / sales
- 6.43
- Price / book
- 31.17
- EPS (TTM)
- 18.01
- Beta
- 1.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 18.24%
- Revenue (TTM)
- 2.84B
- Revenue growth
- 8.50%
- Free cash flow
- 497.78M
- Total cash
- 705.32M
- Total debt
- 171.46M
- Return on equity
- 117.88%
- Shares outstanding
- 27.97M
- Short % of float
- 7.19%
- 50-day average
- 618.33
- 200-day average
- 529.20
Analyst view
Consensus: hold
- Target (low)
- 370.00
- Target (mean)
- 651.31
- Target (high)
- 730.00
- Strong buy1
- Buy1
- Hold11
- Sell1
- Strong sell0
Next earnings
Feb 8, 2027
Expected Feb 8, 2027. Consensus EPS estimate 4.88.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 8, 2027 | Dec 30, 2026 | 4.82 | — | — | — |
| Oct 21, 2026 | Sep 30, 2026 | 4.44 | 4.84 | +0.40 | +9.01% |
| Jul 22, 2026 | Jun 30, 2026 | 3.98 | 4.25 | +0.27 | +6.78% |
| Apr 22, 2026 | Mar 31, 2026 | 3.92 | 4.28 | +0.36 | +9.18% |
| Feb 9, 2026 | Dec 31, 2025 | 4.19 | 4.67 | +0.48 | +11.46% |
| Oct 22, 2025 | Sep 30, 2025 | 3.53 | 3.86 | +0.33 | +9.35% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | BMO Capital | main | Market Perform | Market Perform |
| Oct 23, 2026 | UBS | main | Neutral | Neutral |
| Oct 23, 2026 | Truist Securities | main | Hold | Hold |
| Oct 23, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 23, 2026 | TD Cowen | main | Hold | Hold |
| Oct 7, 2026 | Mizuho | main | Outperform | Outperform |
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- medpace.com
News
- Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
- Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
- Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
- BMO Capital Maintains Market Perform on Medpace Holdings, Raises Price Target to $670
- All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy
- Here's Why Medpace (MEDP) is a Strong Growth Stock
- Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate
- UBS Maintains Neutral on Medpace Holdings, Raises Price Target to $700
- Truist Securities Maintains Hold on Medpace Holdings, Raises Price Target to $633
- Barclays Maintains Equal-Weight on Medpace Holdings, Raises Price Target to $675
Your note
Sign in to keep a note on MEDP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADY KEVIN M. | Chief Financial Officer | Sale | Aug 19, 2026 | 12,830 |
| BURWIG SUSAN ELIZABETH | Officer | Sale | Oct 26, 2026 | 54,012 |
| CARLEY BRIAN T | Director | Sale | Aug 18, 2026 | 27,825 |
| DAVENPORT FRED B JR | Director | Sale | Aug 18, 2026 | 5,798 |
| EWALD STEPHEN P | General Counsel | Sale | May 27, 2026 | 20,343 |
| GEIGER JESSE J | President | Sale | Mar 16, 2026 | 15,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.93% | 2,498,248 | 1.63B | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 7.40% | 2,069,677 | 1.35B | Jun 29, 2026 |
| AQR Capital Management, LLC | 4.57% | 1,278,935 | 833.88M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.05% | 1,133,357 | 738.96M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.67% | 1,026,820 | 669.50M | Jun 29, 2026 |
| State Street Corporation | 2.54% | 710,895 | 463.51M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.88% | 805,328 | 525.08M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.59% | 724,942 | 472.67M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.87% | 523,659 | 341.43M | Jun 29, 2026 |
| T. Rowe Price Equity Funds, Inc.-T. Rowe Price Large-Cap Growth Fund | 1.35% | 376,363 | 245.39M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Quality ETF | 1.18% | 329,256 | 214.68M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.08% | 302,065 | 196.95M | Jun 29, 2026 |